Checkpoint Therapeutics 株価情報 (NASDAQ: CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT) 株価情報

CHECKPOINT THERAPEUTICS INC

Checkpoint Therapeutics

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics Inc

Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 91.13 percent increase over losses of $(2.03) per share from the same period last year.

Earnings

Earnings Misses

News

CLDI

Calidi Biotherapeutics Q1 EPS $(0.18) Misses $(0.15) Estimate

Stock Split

SQFT

SQFTP

SQFTW

Presidio Property Trust Announces 1-For-10 Reverse Stock Split

- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 -
- Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time -
- Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 -
- Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET -
Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>), a clinical stage gene editing company utilizing its novel proprietary ARCUS&#xAE; platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company's first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD) and highlighted a PBGENE-DMD poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17, 2025, in New Orleans, Louisiana.

Biotech

General

DTIL

Precision BioSciences Accelerates Development Of First-in-Class In Vivo Gene Editing Therapy PBGENE-DMD For Duchenne Muscular Dystrophy Targeting Exons 45–55 Hot Spot, IND/CTA Submission Planned For 2025 And Clinical Data Expected In 2026

Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 100 percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $12.46 million which beat the analyst consensus estimate of $12.00 million by 3.81 percent. This is a 7.30 percent increase over sales of $11.61 million the same period last year.

Earnings Beats

GWRS

Global Water Resources Q1 EPS $0.02 Beats $0.01 Estimate, Sales $12.46M Beat $12.00M Estimate

Management

CSCO

Cisco Systems CFO Scott Herren To Retire Effective July 26, 2025; Mark Patterson To Succeed

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 15 years by 4.76% on an annualized basis producing an average annual return of 16.75%. Currently, First Citizens BancShares has a market capitalization of $26.08 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 15 years ago, it would be worth $984.91 today based on a price of $1962.92 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747255516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FCNCA

Here's How Much $100 Invested In First Citizens BancShares 15 Years Ago Would Be Worth Today

Battalion Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BATL#AMEX">BATL</a>) reported quarterly losses of $(0.35) per share. This is a 84.38 percent increase over losses of $(2.24) per share from the same period last year. The company reported $47.48 million in sales this quarter. This is a 4.80 percent decrease over sales of $49.87 million the same period last year.

BATL

Battalion Oil Q1 EPS $(0.35) Up From $(2.24) YoY, Sales $47.48M Down From $49.87M YoY

BZAI

Blaize Holdings Q1 EPS $(1.61), Sales $1.01M

Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23.08 percent. This is a 81.9 percent increase over losses of $(2.21) per share from the same period last year.

ORKA

Oruka Therapeutics Q1 EPS $(0.40) Beats $(0.52) Estimate

Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $(1.74) by 595.4 percent.

JBIO

Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate

Contango Ore (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTGO#AMEX">CTGO</a>) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.21) by 795.24 percent. This is a 12.15 percent increase over losses of $(2.14) per share from the same period last year.

CTGO

Contango Ore Q1 EPS $(1.88) Misses $(0.21) Estimate

Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) reported quarterly losses of $(0.71) per share. This is a 29.09 percent decrease over losses of $(0.55) per share from the same period last year.

AARD

Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY

Enpro Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) today announced the pricing of its previously announced offering of senior notes due 2033 (the "Senior Notes"). The face value of the Senior Notes is $450 million with an annual interest rate of 6.125%. The Senior Notes were priced at 100.0% of the face value. The offer was made in the United States to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to non-U.S. persons in reliance on Regulation S under the Securities Act. The Senior Notes offering is expected to close on May 29, 2025.
Enpro intends to use the net proceeds from the offering to fund the redemption of all of its outstanding 5.75% senior notes due 2026 (the "Outstanding Notes"), to repay a portion of the borrowings under its senior secured revolving credit facility used to fund the repayment on April 9, 2025 of all of its then-outstanding term loans under its senior secured credit facility, and to pay fees and expenses in connection with the offering. The conditional redemption of the Outstanding Notes was announced by Enpro on May 13, 2025.

Offerings

Enpro Inc. Prices Offering Of $450M 6.125% Senior Notes Due 2033

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(1.22) per share. This is a 86.75 percent increase over losses of $(9.21) per share from the same period last year.

ENVB

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Empire Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EP#AMEX">EP</a>) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported $9.00 million in sales this quarter. This is a 4.10 percent decrease over sales of $9.39 million the same period last year.

Empire Petroleum Q1 Adj. EPS $(0.13) Up From $(0.15) YoY, Sales $9.00M Down From $9.39M YoY

Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) sees Q2 sales of $1.500 million-$1.700 million vs $1.52 million analyst estimate.

Guidance

Blaize Holdings Sees Q2 Sales $1.500M-$1.700M vs $1.52M Est

Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) affirms FY2025 sales outlook from $19.00 million-$50.00 million to $19.00 million-$50.00 million.

Blaize Holdings Affirms FY2025 Sales Guidance of $19.00M-$50.00M

MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29.41 percent. This is a 72.73 percent increase over losses of $(1.32) per share from the same period last year.

MTVA

MetaVia Q1 EPS $(0.36) Beats $(0.51) Estimate

Boxlight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) reported quarterly losses of $(1.41) per share. This is a 62.89 percent increase over losses of $(3.80) per share from the same period last year. The company reported $22.40 million in sales this quarter. This is a 39.61 percent decrease over sales of $37.09 million the same period last year.

BOXL

Boxlight Q1 EPS $(1.41) Up From $(3.80) YoY, Sales $22.40M Down From $37.09M YoY

Vroom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) reported quarterly losses of $(1.23) per share. This is a 96.74 percent increase over losses of $(37.68) per share from the same period last year. The company reported $36.20 million in sales this quarter. This is a 3.78 percent increase over sales of $34.88 million the same period last year.

Vroom Q1 EPS $(1.23) Up From $(37.68) YoY, Sales $36.20M Up From $34.88M YoY

Press Releases

CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT

Comments

Checkpoint Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル